Overview
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID). NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of phenylbutazone, mefenamic acid, and indomethacin. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with misoprostol to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).
Indication
Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with misoprostol as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.
Associated Conditions
- Actinic Keratosis (AK)
- Acute Arthritis
- Acute Gouty Arthritis
- Acute Migraine
- Acute Musculoskeletal Pain
- Ankylosing Spondylitis (AS)
- Common Cold
- Fever
- Gout
- Inflammation
- Inflammatory Disease of the Oral Cavity
- Inflammatory Disease of the throat
- Inflammatory Reaction of the Nerve
- Joint Pain
- Juvenile Idiopathic Arthritis (JIA)
- Menstrual Distress (Dysmenorrhea)
- Muscle Inflammation
- Myalgia
- Neuropathic Pain
- Ocular Inflammation
- Osteoarthritis (OA)
- Osteoarthritis of the Knee
- Pain
- Pain caused by Rheumatism
- Pericarditis
- Photophobia
- Postoperative Inflammatory Response
- Postoperative pain
- Primary Dysmenorrhoea
- Radicular Pain
- Rheumatism
- Rheumatoid Arthritis
- Seasonal Allergic Conjunctivitis
- Spinal pain
- Tendon pain
- Vertebral column pain
- Acute Musculoskeletal injury
- Acute, moderate, severe Pain, Inflammatory
- Localized soft tissue rheumatism
- Mild to moderate joint pain
- Mild to moderate pain
- Minor pain
- Perioperative miosis
Research Report
Diclofenac: A Comprehensive Pharmacological and Clinical Review
1. Introduction to Diclofenac
1.1. Overview and Summary
Diclofenac is a well-established phenylacetic acid derivative classified as a non-steroidal anti-inflammatory drug (NSAID).[1] It is primarily utilized for the management of signs and symptoms associated with various arthritic conditions, including osteoarthritis and rheumatoid arthritis.[1] Its therapeutic applications extend to ankylosing spondylitis and a range of other painful states, such as menstrual cramps (primary dysmenorrhea) and acute migraine attacks.[2] The pharmacological profile of diclofenac is characterized by its potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities.[3]
The broad spectrum of indications for diclofenac underscores its efficacy in conditions where prostaglandins play a significant pathogenic role. Prostaglandins are key mediators in inflammation, pain sensitization, and fever development. By inhibiting their synthesis, diclofenac offers relief across a diverse array of clinical scenarios. Its utility in both chronic inflammatory diseases like arthritis and acute painful conditions such as migraines highlights its versatility as a therapeutic agent.[1] This versatility is a direct consequence of its fundamental mechanism of action as an NSAID, which targets the cyclooxygenase (COX) enzymes responsible for prostaglandin production. However, this same mechanism also underpins its potential for adverse effects, particularly concerning the gastrointestinal and cardiovascular systems, which are significant enough to warrant boxed warnings from regulatory authorities like the U.S. Food and Drug Administration (FDA).[3] The widespread and long-standing use of diclofenac implies a considerable clinical impact in pain and inflammation management. Concurrently, this extensive use necessitates a comprehensive understanding and careful consideration of its
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2023/09/25 | Early Phase 1 | Recruiting | |||
2023/09/08 | Early Phase 1 | Recruiting | |||
2023/08/25 | Phase 4 | Recruiting | University Hospital, Strasbourg, France | ||
2023/08/01 | Phase 1 | Completed | Amzell | ||
2023/07/17 | Not Applicable | Terminated | Air Force Military Medical University, China | ||
2023/04/26 | Phase 4 | Completed | Osijek University Hospital | ||
2023/04/18 | Phase 3 | Recruiting | |||
2023/03/02 | Phase 1 | Completed | |||
2022/12/16 | Phase 2 | Completed | |||
2022/11/23 | Phase 3 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Proficient Rx LP | 71205-552 | TOPICAL | 10 mg in 1 g | 4/1/2021 | |
Advanced Rx Pharmacy of Tennessee, LLC | 80425-0189 | ORAL | 75 mg in 1 1 | 2/8/2023 | |
Direct_Rx | 72189-454 | TOPICAL | 16.05 mg in 1 mL | 3/29/2023 | |
H. J. Harkins Company Inc. | 76519-1159 | TOPICAL | 10 mg in 1 1 | 12/8/2017 | |
Amneal Pharmaceuticals LLC | 65162-911 | TOPICAL | 16.05 mg in 1 mL | 12/19/2023 | |
Quality Care Products, LLC | 55700-980 | TOPICAL | 30 mg in 1 g | 8/18/2022 | |
Quality Care Products, LLC | 55700-886 | TOPICAL | 0.013 g in 1 1 | 6/26/2023 | |
Bryant Ranch Prepack | 71335-1183 | ORAL | 75 mg in 1 1 | 2/3/2022 | |
Proficient Rx LP | 71205-450 | TOPICAL | 16.05 mg in 1 mL | 4/1/2020 | |
PD-Rx Pharmaceuticals, Inc. | 43063-467 | ORAL | 50 mg in 1 1 | 3/31/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
VOLTAREN 50 SUPPOSITORY 50 mg | SIN05468P | SUPPOSITORY | 50 mg | 2/22/1991 | |
Panamax Gel | Hsinchu Plant of UBI Pharma Inc. | SIN13706P | GEL | 10.0mg/g | 10/8/2009 |
ALMIRAL GEL 1% w/w | SIN05996P | GEL | 1 g/100 g | 5/27/1991 | |
FENADIUM TABLETS 25 mg | SIN05568P | ENTERIC COATED TABLET | 25 mg | 3/7/1991 | |
NEODOL-50 TABLET 50 mg | SIN09392P | ENTERIC COATED TABLET | 50 mg | 6/19/1997 | |
VOLTAREN 50 TABLET 50 mg | SIN05662P | ENTERIC COATED TABLET | 50 mg | 4/8/1991 | |
VOREN SUPPOSITORIES 25 mg | SIN07656P | SUPPOSITORY | 25 mg | 3/8/1994 | |
VOREN CAPSULE 50 mg | SIN07678P | CAPSULE | 50 mg | 4/5/1994 | |
VOREN TABLET 25 mg | SIN07987P | ENTERIC COATED TABLET | 25 mg | 1/19/1995 | |
VOREN TABLET 50 mg | SIN07975P | ENTERIC COATED TABLET | 50 mg | 12/30/1994 |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
VOLTAREN 24 HOUR PATCH 30MG | N/A | N/A | N/A | 9/14/2009 | |
VOLTAREN 12 HOUR EMULGEL 2.32%W/W | N/A | N/A | N/A | 12/23/2014 | |
NEUROGESIC EMULSIFIED GEL 1%W/V | N/A | N/A | N/A | 7/15/2006 | |
PAINSTOP INJ 25MG/ML | N/A | N/A | N/A | 7/20/1996 | |
DYNAPAR SR 100 TAB 100MG | N/A | N/A | N/A | 6/10/2010 | |
XTRA CAP 50MG | N/A | N/A | N/A | 9/29/1999 | |
VOLTAREN SR PROLONGED-RELEASE TABLETS 100MG | N/A | N/A | N/A | 2/15/2019 | |
VOLTAREN TAB 50MG ENTERIC COATED | N/A | N/A | N/A | 4/30/1992 |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
TERRYWHITE CHEMMART ANTI-INFLAMMATORY PAIN RELIEF GEL diclofenac sodium 10mg/g gel tube | 303482 | Medicine | A | 5/25/2018 | |
DOFIDAZ diclofenac sodium 3% w/w gel tube | 443217 | Medicine | A | 3/6/2025 | |
Voltaren 50 tablet | 66880 | Medicine | A | 11/19/1998 | |
VOLTAREN PAIN RELIEF GEL diclofenac diethylamine 11.6mg/g gel tube | 47676 | Medicine | A | 4/21/1994 | |
VOLTAREN suppository blister pack | 37582 | Medicine | A | 10/30/1992 | |
APOHEALTH ANTI-INFLAMMATORY PAIN RELIEF RAPID 25 diclofenac potassium 25 mg tablet blister pack | 407498 | Medicine | A | 4/11/2023 | |
PHARMACY CHOICE DICLOFENAC 25 diclofenac potassium 25 mg soft capsule blister pack | 461974 | Medicine | A | 9/5/2024 | |
PHARMACY HEALTH DICLOFENAC POTASSIUM RAPID 25 diclofenac potassium 25 mg tablet blister pack | 422672 | Medicine | A | 9/27/2023 | |
VOLTAREN diclofenac sodium 25mg suppository | 96810 | Medicine | A | 5/25/2004 | |
Voltaren 25 Tablets | 11072 | Medicine | A | 8/2/1991 |
Health Canada Drug Approvals
View More Health Canada Approvals
Sign in to access additional Health Canada approved drug information with detailed regulatory data.
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
TEVA-DICLOFENAC SR | teva canada limited | 02158582 | Tablet (Extended-Release) - Oral | 75 MG | 12/31/1995 |
TEVA-DICLOFENAC EC | teva canada limited | 00808547 | Tablet (Enteric-Coated) - Oral | 50 MG | 12/31/1989 |
RIVA-DICLOFENAC 100MG SR TABLETS | laboratoire riva inc. | 02240735 | Tablet (Extended-Release) - Oral | 100 MG | 8/27/1999 |
PMS-DICLOFENAC | 02356783 | Solution - Topical | 1.5 % / W/W | 12/2/2014 | |
PMS-DICLOFENAC K | 02239753 | Tablet - Oral | 50 MG | 3/4/1999 | |
DICLOFENAC K | sanis health inc | 02351684 | Tablet - Oral | 50 MG | 6/15/2010 |
APO-DICLO SR | 02091194 | Tablet (Extended-Release) - Oral | 100 MG / SRT | 12/31/1994 | |
PMS-DICLOFENAC-SR | 02231505 | Tablet (Extended-Release) - Oral | 100 MG | 11/28/1997 | |
VOLTAREN EMULGEL JOINT PAIN EXTRA STRENGTH | haleon canada ulc | 02465043 | Gel - Topical | 2.32 % / W/W | 6/27/2018 |
MINT-DICLOFENAC | mint pharmaceuticals inc | 02475197 | Solution - Ophthalmic | 0.1 % / W/V | 9/9/2020 |
CIMA AEMPS Drug Approvals
View More CIMA AEMPS Approvals
Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
View More Philippines FDA Approvals
Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
View More Saudi SFDA Approvals
Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
View More Malaysia NPRA Approvals
Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
View More UK EMC Drug Information
Sign in to access additional UK EMC drug information with detailed pharmaceutical data.
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.